Dimensional Fund Advisors LP increased its position in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 103.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 685,877 shares of the company’s stock after buying an additional 349,380 shares during the period. Dimensional Fund Advisors LP owned approximately 2.81% of USANA Health Sciences worth $41,976,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Rothschild Asset Management Inc. acquired a new stake in USANA Health Sciences during the third quarter worth $266,000. Robeco Institutional Asset Management B.V. acquired a new stake in USANA Health Sciences during the third quarter worth $271,000. Aperio Group LLC raised its stake in USANA Health Sciences by 12.7% in the third quarter. Aperio Group LLC now owns 2,207 shares of the company’s stock worth $305,000 after buying an additional 248 shares during the last quarter. Ifrah Financial Services Inc. raised its stake in USANA Health Sciences by 9.2% in the third quarter. Ifrah Financial Services Inc. now owns 2,645 shares of the company’s stock worth $366,000 after buying an additional 222 shares during the last quarter. Finally, Jensen Investment Management Inc. acquired a new stake in USANA Health Sciences during the third quarter worth $490,000. Institutional investors and hedge funds own 21.21% of the company’s stock.
USANA Health Sciences, Inc. (NYSE:USNA) traded down 0.35% during trading on Friday, reaching $56.60. 46,669 shares of the company’s stock traded hands. USANA Health Sciences, Inc. has a one year low of $53.35 and a one year high of $75.00. The firm’s 50 day moving average price is $57.23 and its 200-day moving average price is $79.92. The stock has a market cap of $1.39 billion, a P/E ratio of 14.19 and a beta of 1.07.
USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, February 7th. The company reported $0.87 EPS for the quarter, missing the Zacks’ consensus estimate of $0.94 by $0.07. USANA Health Sciences had a return on equity of 35.36% and a net margin of 9.89%. The business had revenue of $252.90 million for the quarter, compared to analyst estimates of $253.52 million. During the same quarter in the previous year, the business posted $0.92 earnings per share. The company’s revenue was up 8.7% compared to the same quarter last year. On average, equities analysts anticipate that USANA Health Sciences, Inc. will post $4.01 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by BBNS and is owned by of BBNS. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://baseballnewssource.com/markets/dimensional-fund-advisors-lp-buys-349380-shares-of-usana-health-sciences-inc-usna-updated-updated/525523.html.
USNA has been the topic of several analyst reports. Zacks Investment Research lowered shares of USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research report on Saturday, February 11th. Pivotal Research dropped their price target on shares of USANA Health Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, February 8th.
In other news, major shareholder Global Ltd Gull sold 10,040 shares of USANA Health Sciences stock in a transaction dated Tuesday, April 4th. The stock was sold at an average price of $56.69, for a total transaction of $569,167.60. Following the completion of the sale, the insider now directly owns 12,524,696 shares in the company, valued at approximately $710,025,016.24. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Myron W. Wentz sold 40,000 shares of USANA Health Sciences stock in a transaction dated Wednesday, April 5th. The shares were sold at an average price of $56.81, for a total value of $2,272,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 120,000 shares of company stock valued at $6,805,102 over the last 90 days. Corporate insiders own 57.00% of the company’s stock.
About USANA Health Sciences
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with our FREE daily email newsletter.